定时光照治疗帕金森病相关嗜睡与睡眠的随机临床试验
这项随机、安慰剂对照临床试验在31例伴日间过度嗜睡(EDS)的帕金森病(PD)患者中,比较明亮光照与暗红光照射每日两次、每次1小时、共14天的效果。明亮光照显著改善EDS(Epworth嗜睡量表评分基线15.81 vs 干预后11.19),两种光照均改善睡眠质量,光照耐受性良好,可作为改善PD睡眠-觉醒周期的可行干预。
要点
- 明亮光照可显著改善帕金森病患者的日间过度嗜睡。
- 明亮与暗红光照射均改善睡眠质量量表评分。
- 光照治疗耐受性良好,但最佳参数尚需进一步研究。
核心结论
- 光照治疗耐受性良好,可能成为改善帕金森病患者睡眠-觉醒周期的可行干预。
- 仍需进一步研究确定帕金森病光照治疗的最佳参数。
研究设计与样本
- 随机、安慰剂对照临床干预研究,设于西北大学与拉什大学的帕金森病中心。
- 纳入31例接受稳定多巴胺能治疗、Epworth嗜睡量表评分≥12且无认知障碍或原发性睡眠障碍的帕金森病患者。
- 按1:1随机接受明亮光照或暗红光光照(对照),每日两次、每次1小时间隔,共14天。
主要发现
- 明亮光照组Epworth嗜睡量表评分从基线15.81(3.10)降至干预后11.19(3.31)。
- 明亮光照组匹兹堡睡眠质量指数从7.88(4.11)降至6.25(4.27),暗红光组从8.87(2.83)降至7.33(3.52)。
- 明亮光照组帕金森病睡眠量表从97.24(22.49)升至106.98(19.37),暗红光组从95.11(19.86)升至99.28(16.94)。
- 明亮光照改善夜间觉醒次数(1.51[1.03]降至0.92[0.97])、睡眠日记睡眠质量评分(3.03[1.01]升至3.53[0.91])及入睡容易程度评分(2.32[0.89]降至1.83[0.88])。
- 活动记录仪显示平均活动计数从165.01(66.87)增至194.59(87.81)。
关键数值与推荐
- 主要结局为明亮光照与暗红光光照相比Epworth嗜睡量表评分的变化。
- 次要结局包括匹兹堡睡眠质量指数、帕金森病睡眠量表、日间嗜睡视觉模拟量表及睡眠日志和活动记录仪指标。
临床怎么用
- 对于伴日间过度嗜睡且无认知障碍或原发性睡眠障碍的帕金森病患者,可考虑试用光照治疗。
- 明亮光照每日两次、每次1小时、共14天的方案在本研究中耐受性良好。
局限性
- 样本量较小(31例),可能限制结果的普遍性。
- 光照治疗的最佳参数(如强度、时长、时机)尚未确定,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Impaired sleep and alertness are some of the most common nonmotor manifestations of Parkinson disease (PD) and currently have only limited treatment options. Light therapy (LT), a widely available treatment modality in sleep medicine, has not been systematically studied in the PD population. OBJECTIVE: To determine the safety and efficacy of LT on excessive daytime sleepiness (EDS) associated with PD. DESIGN, SETTINGS, AND PARTICIPANTS: This randomized, placebo-controlled, clinical intervention study was set in PD centers at Northwestern University and Rush University. Participants were 31 patients with PD receiving stable dopaminergic therapy with coexistent EDS, as assessed by an Epworth Sleepiness Scale score of 12 or greater, and without cognitive impairment or primary sleep disorder. Participants were randomized 1:1 to receive bright LT or dim-red LT (controlled condition) twice daily in 1-hour intervals for 14 days. This trial was conducted between March 1, 2007, and October 31, 2012. Data analysis of the intention-to-treat population was conducted from November 1, 2012, through April 30, 2016. MAIN OUTCOMES AND MEASURES: The primary outcome measure was the change in the Epworth Sleepiness Scale score comparing the bright LT with the dim-red LT. Secondary outcome measures included the Pittsburgh Sleep Quality Index score, the Parkinson's Disease Sleep Scale score, the visual analog scale score for daytime sleepiness, and sleep log-derived and actigraphy-derived metrics. RESULTS: Among the 31 patients (13 males and 18 females; mean [SD] disease duration, 5.9 [3.6] years), bright LT resulted in significant improvements in EDS, as assessed by the Epworth Sleepiness Scale score (mean [SD], 15.81 [3.10] at baseline vs 11.19 [3.31] after the intervention). Both bright LT and dim-red LT were associated with improvements in sleep quality as captured by mean (SD) scores on the Pittsburg Sleep Quality Index (7.88 [4.11] at baseline vs 6.25 [4.27] after bright LT, and 8.87 [2.83] at baseline vs 7.33 [3.52] after dim-red LT) and the Parkinson's Disease Sleep Scale (97.24 [22.49] at baseline vs 106.98 [19.37] after bright LT, and 95.11 [19.86] at baseline vs 99.28 [16.94] after dim-red LT). Bright LT improved several self-reported mean (SD) sleep metrics, including sleep fragmentation (number of overnight awakenings, 1.51 [1.03] at baseline vs 0.92 [0.97] after the intervention), sleep quality (sleep diary score, 3.03 [1.01] at baseline vs 3.53 [0.91] after the intervention), and ease of falling asleep (sleep diary score, 2.32 [0.89] at baseline vs 1.83 [0.88] after the intervention). Light therapy was associated with increased daily physical activity as assessed by actigraphy (average activity [SD] counts, 165.01 [66.87] at baseline vs 194.59 [87.81] after the intervention). CONCLUSIONS AND RELEVANCE: Light therapy was well tolerated and may be a feasible intervention for improving the sleep-wake cycles in patients with PD. Further studies are required to determine optimal parameters of LT for PD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01338649.
引用
- Videnovic A, Klerman EB, Wang W, et al. Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017. PMID: 28241159. doi:10.1001/jamaneurol.2016.5192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。